

Datasheet: HCA185

Description:	HUMAN ANTI BEVACIZUMAB
Specificity:	BEVACIZUMAB
Other names:	AVASTIN
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD17976_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

IgG concentration 1.0 mg/ml

Immunogen

Bevacizumab

Specificity

Human Anti-Bevacizumab Antibody, clone AbD17976_hlgG1 is an affinity-matured, inhibitory, anti-idiotypic antibody that recognizes the humanized monoclonal antibody

drugs bevacizumab and ranibizumab, and their biosimilar products.

Clone AbD17976_hlgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a positive control or calibrator in an anti-drug antibody (ADA) assay.

This Anti-Bevacizumab Antibody cross-reacts with the drug ranibizumab (Lucentis). Ranibizumab is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab; it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab.

Bevacizumab (trade name Avastin) is a humanized monoclonal antibody (IgG1/kappa) that inhibits angiogenesis by binding to vascular endothelial growth factor alpha (VEGF-A). VEGF-A is a potent stimulator of angiogenesis of both normal and cancerous cells, and acts as a regulator of vasculogenesis. Bevacizumab is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.

[View a summary of all anti-bevacizumab antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K^D=0.4$ nM by real time, label-free molecular interaction analysis on immobilized bevacizumab.
ELISA	This product is suitable for use in direct ELISA applications. This antibody is fully human and can be used as a reference standard in an ADA assay. Protocol: ADA bridging ELISA
References	1. Iwamoto, N. <i>et al.</i> (2018) Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal Biochem. 540-541: 30-7.
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Avastin is a trademark of Genentech Inc.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

Related Products

Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)

[HUMAN ANTI BEVACIZUMAB \(HCA184\)](#)

[HUMAN ANTI BEVACIZUMAB \(HCA182\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

From March 15, 2021, we will no longer supply printed datasheets with our products.

Look out for updates on how to access your digital version at bio-rad-antibodies.com

'M371596:200612'

Printed on 02 Mar 2021

© 2021 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)